Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Cachexia is “a complex metabolic syndrome associated with underlying illness and characterized by muscle loss, with or without loss of fat”. There are various forms of loss of lean muscle mass or wasting in end stage kidney disease (ESKD) including renal cachexia and protein energy wasting (PEW). In ESKD, cachexia and the PEW syndrome are closely related, as recent understanding indicates that PEW corresponds to the initial state of a continuous process that progresses to cachexia. Cachexia is a major contributor to morbidity and to healthcare costs, therefore there is an urgency to develop and test interventions which have a real possibility of counterbalancing these costs while also improving outcomes for this vulnerable population.
Patients with or at risk of renal cachexia need interventions which help to increase their capacity for physical functioning, build lean muscle mass, maintain or increase their weight and stabilise abnormal biochemistry related to cachexia, to increase their quality of life and prolong survival. Empirical, theoretical, and Cochrane review data highlight the potential for multimodal interventions which work synergistically to target the multifactorial pathophysiology associated with cachexia. Based on this, with additional input from key stakeholders including patients and public (PPI), the MultiModal Integrative intervention combining Exercise, Anti-inflammatory and Dietary counselling - MMIEAD was developed for renal cachexia.
MMIEAD is the first evidence informed, theoretically driven multimodal intervention for renal cachexia. The rationale for the MMIEAD intervention in renal cachexia, which is currently being trialled in a competitively funded feasibility cluster randomised controlled trial (cRCT) with built in process and economic evaluations, will be described (Trial registration number: NCT07107087). The development of the current MMIEAD cRCT trial and key trial parameters will be presented. Alongside this, co-design of key elements of the intervention will be highlighted, which target optimisation of recruitment, retention and adherence to MMIEAD.
This programme of work is designed to have a substantial impact for patients, informal carers and health care professionals and aligns with the United Kingdom (UK) National Service Framework for Renal Services ‘Standard one: A patient-centred service’ to improve quality of life for individuals with renal disease and their carers’ promoted by The European Kidney Health Alliance, The UK Kidney Association Kidney and Kidney Care UK. The programme of work focuses on renal cachexia which affects 16% of those diagnosed with ESKD undergoing haemodialysis and creates the potential for extensive impact in terms of the number of direct stakeholders benefitting from the MMIEAD intervention.
1.
